Display options
Cite
Amberger C, Chetboul V, Bomassi E, et al. Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol. 2004;6(2):9-16doi: 10.1016/S1760-2734(06)70053-4.
Amberger, C., Chetboul, V., Bomassi, E., Rougier, S., Woehrlé, F., Thoulon, F. (2004). Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 6(2), 9-16. https://doi.org/10.1016/S1760-2734(06)70053-4
Amberger, Chris, et al. "Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure." Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology vol. 6,2 (2004): 9-16. doi: https://doi.org/10.1016/S1760-2734(06)70053-4
Amberger C, Chetboul V, Bomassi E, Rougier S, Woehrlé F, Thoulon F. Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol. 2004 Nov;6(2):9-16. doi: 10.1016/S1760-2734(06)70053-4. PMID: 19083305.
Copy Download .nbib Format: NLM
Share it on

J Vet Cardiol. 2004 Nov;6(2):9-16. doi: 10.1016/S1760-2734(06)70053-4.

Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology

Chris Amberger, Valérie Chetboul, Eric Bomassi, Sandrine Rougier, Frédérique Woehrlé, Fabrice Thoulon,

Affiliations

  1. 96 rue de la Servette, CH-1202 Geneva, Switzerland.

PMID: 19083305 DOI: 10.1016/S1760-2734(06)70053-4

Abstract

OBJECTIVE: To compare the efficacy and tolerability of the long-term administration of two different angiotensin-converting enzyme inhibitors, imidapril and enalapril, in a multicentric, prospective, randomized parallel-group scheme clinical trial in dogs with naturally acquired heart disease.

ANIMALS: One hundred twenty eight dogs with clinical signs of heart failure (stage II (64-50%) - III (45-35%) - IV (19-15%) New York Heart Association) caused by chronic valvular disease or dilated cardiomyopathy were selected.

PROCEDURE: Imidapril (minimum dosage 0.25 mg/kg) or enalapril (median dosage 0.5 mg/kg) was administered orally once daily for 12 months, either alone or as an add-on therapy to diuretics and/or digoxin.

RESULTS: The primary outcome measure was the quality of life score after 3 months of therapy. Sixty-one percent of the dogs in the imidapril group (36/59) and 52 % in the enalapril group (30/58) were considered responders. After 12 months, a clear improvement compared to baseline was maintained in each treatment group for most parameters reflecting the quality of life such as fatigue, exercise tolerance, dyspnea, cough and general condition. Quality of life scores and survival times were similar in both groups after 12 months. Both drugs were well tolerated over the one-year follow-up.

CONCLUSIONS: Imidapril proved to be as effective as the reference drug enalapril in the treatment of dogs with NYHA class II-IV heart failure. As with enalapril, imidapril was well tolerated during the long-term treatment period of one year in the dose range used in the study.

Publication Types